pioglitazone has been researched along with Diabetic Neuropathies in 17 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To define the components of the metabolic syndrome that contribute to diabetic polyneuropathy (DPN) in type 2 diabetes mellitus (T2DM), we treated the BKS db/db mouse, an established murine model of T2DM and the metabolic syndrome, with the thiazolidinedione class drug pioglitazone." | 3.81 | The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes. ( Backus, C; Brosius, FC; Dauch, JR; Feldman, EL; Hayes, JM; Hinder, LM; Hur, J; Kretzler, M; Pennathur, S, 2015) |
| "Rats were tested for thermal hyperalgesia and mechanical allodynia." | 1.56 | Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ. ( El-Gawly, HW; El-Sherbeeny, NA; Elaidy, SM; Elkholy, SE; Toraih, EA, 2020) |
| " Therefore, we tested the hypothesis that chronic administration of pioglitazone would reduce PDN in Zucker Diabetic Fatty (ZDF(fa/fa) [ZDF]) rats." | 1.43 | Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes. ( Adkins, BG; Anderson, KL; Donahue, RR; Griggs, RB; Taylor, BK; Thibault, O, 2016) |
| "Chronic pain is a common complication of diabetes." | 1.42 | Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments. ( Byrne, FM; Chapman, V; Cheetham, S; Vickers, S, 2015) |
| "Treatment of pioglitazone lowered blood glucose level and prevented delay of MNCV in SDT fatty rats." | 1.38 | Diabetic peripheral neuropathy in Spontaneously Diabetic Torii-Lepr(fa) (SDT fatty) rats. ( Kemmochi, Y; Matsushita, M; Mera, Y; Ohta, T; Sasase, T; Sato, E; Tadaki, H; Tomimoto, D; Yamaguchi, T, 2012) |
| "Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes)." | 1.31 | Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. ( Bíró, K; Jednákovits, A; Kukorelli, T; Kürthy, M; Mogyorósi, T; Nagy, K; Tálosi, L, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (11.76) | 29.6817 |
| 2010's | 10 (58.82) | 24.3611 |
| 2020's | 5 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Santos, DFS | 1 |
| Donahue, RR | 2 |
| Laird, DE | 1 |
| Oliveira, MCG | 1 |
| Taylor, BK | 2 |
| Elkholy, SE | 1 |
| Elaidy, SM | 1 |
| El-Sherbeeny, NA | 1 |
| Toraih, EA | 1 |
| El-Gawly, HW | 1 |
| Ponirakis, G | 2 |
| Abdul-Ghani, MA | 2 |
| Jayyousi, A | 2 |
| Almuhannadi, H | 2 |
| Petropoulos, IN | 2 |
| Khan, A | 2 |
| Gad, H | 2 |
| Migahid, O | 2 |
| Megahed, A | 2 |
| DeFronzo, R | 2 |
| Mahfoud, Z | 2 |
| Hassan, M | 1 |
| Al Hamad, H | 1 |
| Ramadan, M | 1 |
| Alam, U | 1 |
| Malik, RA | 2 |
| Bakkar, NZ | 1 |
| Mougharbil, N | 2 |
| Mroueh, A | 2 |
| Kaplan, A | 2 |
| Eid, AH | 2 |
| Fares, S | 1 |
| Zouein, FA | 2 |
| El-Yazbi, AF | 2 |
| Zirie, MA | 1 |
| Al-Mohannadi, S | 1 |
| Qazi, M | 1 |
| AlMarri, F | 1 |
| Al-Khayat, F | 1 |
| Shokrzadeh, M | 1 |
| Mirshafa, A | 1 |
| Yekta Moghaddam, N | 1 |
| Birjandian, B | 1 |
| Shaki, F | 1 |
| Al-Assi, O | 1 |
| Ghali, R | 1 |
| de Anda-Jáuregui, G | 1 |
| Guo, K | 1 |
| McGregor, BA | 1 |
| Feldman, EL | 3 |
| Hur, J | 3 |
| Jin, HY | 1 |
| Lee, KA | 1 |
| Wu, JZ | 1 |
| Baek, HS | 1 |
| Park, TS | 1 |
| Byrne, FM | 1 |
| Cheetham, S | 1 |
| Vickers, S | 1 |
| Chapman, V | 1 |
| Dauch, JR | 1 |
| Hinder, LM | 2 |
| Hayes, JM | 1 |
| Backus, C | 1 |
| Pennathur, S | 2 |
| Kretzler, M | 2 |
| Brosius, FC | 2 |
| Griggs, RB | 1 |
| Adkins, BG | 1 |
| Anderson, KL | 1 |
| Thibault, O | 1 |
| Park, M | 1 |
| Rumora, AE | 1 |
| Eichinger, F | 1 |
| Hempe, J | 1 |
| Elvert, R | 1 |
| Schmidts, HL | 1 |
| Kramer, W | 1 |
| Herling, AW | 1 |
| Yamaguchi, T | 1 |
| Sasase, T | 1 |
| Mera, Y | 1 |
| Tomimoto, D | 1 |
| Tadaki, H | 1 |
| Kemmochi, Y | 1 |
| Ohta, T | 1 |
| Sato, E | 1 |
| Matsushita, M | 1 |
| Ota, T | 1 |
| Osawa, K | 1 |
| Kürthy, M | 1 |
| Mogyorósi, T | 1 |
| Nagy, K | 1 |
| Kukorelli, T | 1 |
| Jednákovits, A | 1 |
| Tálosi, L | 1 |
| Bíró, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)[NCT00244244] | Phase 2 | 80 participants | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for pioglitazone and Diabetic Neuropathies
| Article | Year |
|---|---|
Effect of treatment with exenatide and pioglitazone or basal-bolus insulin on diabetic neuropathy: a substudy of the Qatar Study.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Exenatide; Glycated Hemoglobin; Hum | 2020 |
Insulin resistance limits corneal nerve regeneration in patients with type 2 diabetes undergoing intensive glycemic control.
Topics: Cornea; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Exenatide; Female; Glycated Hemoglobin; Gl | 2021 |
15 other studies available for pioglitazone and Diabetic Neuropathies
| Article | Year |
|---|---|
The PPARγ agonist pioglitazone produces a female-predominant inhibition of hyperalgesia associated with surgical incision, peripheral nerve injury, and painful diabetic neuropathy.
Topics: Analgesics; Animals; Diabetic Neuropathies; Disease Models, Animal; Female; Hyperalgesia; Male; Mice | 2022 |
Neuroprotective effects of ranolazine versus pioglitazone in experimental diabetic neuropathy: Targeting Nav1.7 channels and PPAR-γ.
Topics: Animals; Behavior, Animal; Comorbidity; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diet | 2020 |
Worsening baroreflex sensitivity on progression to type 2 diabetes: localized vs. systemic inflammation and role of antidiabetic therapy.
Topics: Animals; Baroreflex; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dia | 2020 |
Mitochondrial dysfunction contribute to diabetic neurotoxicity induced by streptozocin in mice: protective effect of Urtica dioica and pioglitazone.
Topics: Animals; Antioxidants; Biomarkers; Brain; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dr | 2018 |
Cardiac Autonomic Neuropathy as a Result of Mild Hypercaloric Challenge in Absence of Signs of Diabetes: Modulation by Antidiabetic Drugs.
Topics: Animals; Diabetic Cardiomyopathies; Diabetic Neuropathies; Dietary Fats; Energy Intake; Glucose Into | 2018 |
Pathway crosstalk perturbation network modeling for identification of connectivity changes induced by diabetic neuropathy and pioglitazone.
Topics: Animals; Diabetic Neuropathies; Mice; Models, Biological; Pioglitazone; Systems Biology | 2019 |
The neuroprotective benefit from pioglitazone (PIO) addition on the alpha lipoic acid (ALA)-based treatment in experimental diabetic rats.
Topics: Animals; Axons; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Drug Therapy, | 2014 |
Characterisation of pain responses in the high fat diet/streptozotocin model of diabetes and the analgesic effects of antidiabetic treatments.
Topics: Animal Feed; Animals; Behavior, Animal; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neu | 2015 |
The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes.
Topics: Animals; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Models, Animal; Hypo | 2015 |
Pioglitazone Inhibits the Development of Hyperalgesia and Sensitization of Spinal Nociresponsive Neurons in Type 2 Diabetes.
Topics: Administration, Oral; Analgesics; Animals; Central Nervous System Sensitization; Cold Temperature; D | 2016 |
Comparative RNA-Seq transcriptome analyses reveal distinct metabolic pathways in diabetic nerve and kidney disease.
Topics: Animals; Computational Biology; Diabetic Nephropathies; Diabetic Neuropathies; Gene Expression Profi | 2017 |
Appropriateness of the Zucker Diabetic Fatty rat as a model for diabetic microvascular late complications.
Topics: Animals; Blood Chemical Analysis; Caloric Restriction; Diabetes Mellitus, Type 2; Diabetic Nephropat | 2012 |
Diabetic peripheral neuropathy in Spontaneously Diabetic Torii-Lepr(fa) (SDT fatty) rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Disease Model | 2012 |
Marked improvement of glycaemic control with pioglitazone in a Type 2 diabetic patient associated with Charcot-Marie-Tooth disease.
Topics: Body Weight; Charcot-Marie-Tooth Disease; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; | 2003 |
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
Topics: Animals; Diabetic Neuropathies; Guanidines; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; | 2002 |